New malaria drug ready for launch | InPharmPosted: July 5, 2012
Eurartesim, (dihydroartemisinin piperaquine: DHA-PQP), was co-developed by Italian pharma company Sigma Tau and the not-for-profit research foundation Medicines for Malaria Venture (MMV).
The drug is now ready for delivery to Cambodia, the first malaria endemic country to place an order for this newly approved treatment. Cambodia prioritised the use of DHA-PQP as a first line drug and was awaiting EMA approval to allow procurement of this product using international donor funds.
The World Health Organisation’s standard treatment guidelines recommend DHA-PQP as a highly effective ACT in curing uncomplicated malaria.